Partnering | In a team, you do better
We welcome license or co-develop opportunities for our proprietary Triomab® antibody platform. We bring our partners comprehensive expertise in bio-pharmaceutical production as well as clinical development know-how in Triomab® antibodies.
Based on the nature of immune cell engaging therapies, Lindis Biotech’s pipeline products are also open to combination therapy collaborations of different types.
License or co-develop opportunities are welcome!
LintonPharm is our strategic partner in Guangzhou, China for the development of Triomab® and Fleximab® antibodies in Asia.
University Hospital Leipzig
Institute for transfusion medicine, Dr. med. Raymund Buhmann.
The collaboration with the University Hospital in Leipzig, Germany aims at the development of Triomab® – armed immune effector cells for the treatment of hematological and oncological neoplasia.
German research centre for environmental health
- Prof. Dr. Reinhard Zeidler: Abteilung Genvektoren. Deutsches Zentrum für Infektionsforschung
With the German research centre for environmental health we collaborate in diverse translational research projects.
- Department of Pediatrics, Division of Oncology and Hematology (PD Dr. med. Annette Künkele)
Together with our partner we promote the non-clinical development of GD2-specific Triomab® antibodies.
Image Credits: ryanking999 | 317223309 | Adobe Stock